Financials Immunovia AB

Equities

IMMNOV

SE0006091997

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm 11:29:30 2024-04-26 am EDT 5-day change 1st Jan Change
2.055 SEK +2.75% Intraday chart for Immunovia AB +17.16% +15.97%

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 1,520 2,691 3,530 2,698 1,697 595.2
Enterprise Value (EV) 1 1,327 2,305 3,304 2,262 1,443 526.7
P/E ratio -32.8 x -29.5 x -30.7 x -17.4 x -10.9 x -3.54 x
Yield - - - - - -
Capitalization / Revenue 62.8 x 106 x 9,916 x 7,452 x 2,011 x 520 x
EV / Revenue 54.9 x 90.8 x 9,282 x 6,250 x 1,710 x 460 x
EV / EBITDA -30 x -27 x -29.9 x -17.3 x -8.96 x -2.84 x
EV / FCF -21.7 x -25.9 x -38.8 x -19.1 x -12.5 x -5.04 x
FCF Yield -4.6% -3.86% -2.58% -5.23% -8.01% -19.8%
Price to Book 6.42 x 5.83 x 9.87 x 4.5 x 3.91 x 2.44 x
Nbr of stocks (in thousands) 17,318 19,531 19,655 22,632 22,632 22,632
Reference price 2 87.75 137.8 179.6 119.2 75.00 26.30
Announcement Date 3/20/18 3/4/19 3/20/20 3/12/21 3/10/22 4/21/23
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 24.19 25.38 0.356 0.362 0.844 1.145
EBITDA 1 -44.31 -85.45 -110.5 -130.4 -161.1 -185.2
EBIT 1 -45.58 -88.23 -114.4 -134.7 -166.7 -191.2
Operating Margin -188.42% -347.58% -32,120.79% -37,203.87% -19,756.04% -16,699.48%
Earnings before Tax (EBT) 1 -45.23 -86.53 -114.5 -146 -156 -168.1
Net income 1 -45.23 -86.54 -114.5 -146 -156 -168.1
Net margin -186.99% -340.91% -32,168.82% -40,340.61% -18,479.38% -14,680.52%
EPS 2 -2.671 -4.666 -5.852 -6.843 -6.892 -7.430
Free Cash Flow 1 -61.07 -89.05 -85.21 -118.4 -115.6 -104.5
FCF margin -252.47% -350.8% -23,936.38% -32,697.51% -13,695.63% -9,128.88%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/20/18 3/4/19 3/20/20 3/12/21 3/10/22 4/21/23
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3
Net sales 1 - 0.386 0.344 - 0.108 0.381
EBITDA 1 - -33.72 -44.68 - -44.45 -35.78
EBIT 1 - -39.94 -50.88 - -50.79 -41.92
Operating Margin - -10,346.63% -14,789.83% - -47,025% -11,001.57%
Earnings before Tax (EBT) 1 - -36.13 -47.13 - -33.73 -22.93
Net income 1 -49.26 -36.13 -47.13 - -33.73 -22.93
Net margin - -9,360.36% -13,700.29% - -31,227.78% -6,018.9%
EPS 2 -2.180 -1.600 -2.080 -1.950 -1.490 -1.010
Dividend per Share - - - - - -
Announcement Date 8/19/21 11/11/21 2/17/22 4/28/22 8/24/22 11/10/22
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 192 386 226 435 254 68.5
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -61.1 -89 -85.2 -118 -116 -105
ROE (net income / shareholders' equity) -17.6% -24.8% -27.9% -30.5% -30.2% -49.6%
ROA (Net income/ Total Assets) -10.7% -15.1% -15.9% -15.6% -18% -30.1%
Assets 1 424.1 571.3 718.5 937.3 864.3 558.7
Book Value Per Share 2 13.70 23.70 18.20 26.50 19.20 10.80
Cash Flow per Share 2 11.10 19.80 13.40 20.70 12.70 4.690
Capex 1 5.37 9.06 6.03 4 3.1 1.26
Capex / Sales 22.18% 35.68% 1,694.94% 1,104.42% 367.42% 109.69%
Announcement Date 3/20/18 3/4/19 3/20/20 3/12/21 3/10/22 4/21/23
1SEK in Million2SEK
Estimates
  1. Stock Market
  2. Equities
  3. IMMNOV Stock
  4. Financials Immunovia AB